Further investigation of how mutations in the histone-binding regions of the PBRM1 BAH1 and BAH2 domains disrupt transcriptional networks associated with cancer development, particularly clear cell renal carcinoma, should drive the design of novel treatments for PBRM1-linked cancers. Here, PBRM1 is linked to cancer.